Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pitfalls of histopathological evaluation of EUS guided microbiopsies from pancreatic cystic neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Germ Cell Neoplasia In Situ (GCNIS). Evolution of the Current Nomenclature for Testicular Pre-invasive Germ Cell Malignancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mikromiljøet som med- og modspiller i B-celle-non-Hodgkin-lymfomer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Suet K Loo
  • Ewe S Ch'ng
  • Md Salzihan Md Salleh
  • Alison H Banham
  • Lars M Pedersen
  • Michael B Møller
  • Tina M Green
  • Kah K Wong
Vis graf over relationer

AIMS: Transient receptor potential channel melastatin 4 (TRPM4) is an ion channel that regulates influx of calcium cations (Ca2+ ). Recent studies suggest that TRPM4 is an oncoprotein, and its up-regulated transcript level has been reported in diffuse large B cell lymphoma (DLBCL). We aimed to investigate TRPM4 protein expression pattern in non-malignant tissues and DLBCL cases, and its association with clinico-demographic parameters and survival in DLBCL.

METHODS AND RESULTS: Analysis of publicly available DLBCL microarray data sets showed that TRPM4 transcripts were up-regulated in DLBCL compared to normal germinal centre B (GCB) cells, were expressed more highly in the activated B cell-like DLBCL (ABC-DLBCL) subtype and higher TRPM4 transcripts conferred worse overall survival (OS) in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-treated DLBCL cases (P < 0.05). Our immunohistochemical analysis showed that TRPM4 was expressed in various human tissues but not in normal B cells within lymphoid tissues (reactive tonsil, lymph node and appendix). TRPM4 protein was present in 26% (n = 49 of 189) of our cohort of R-CHOP-treated DLBCL cases and this was associated significantly with more aggressive clinical parameters, including higher lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) scores or stage (P < 0.01 for each of the parameters) and the ABC-DLBCL subtype (P = 0.016). TRPM4 positivity conferred significantly worse OS (P = 0.004) and progression-free survival (PFS) (P = 0.005). Worse OS remained associated significantly with TRPM4 positivity in multivariate analysis, including higher International Prognostic Index (IPI) or the non-GCB DLBCL phenotype (P < 0.05).

CONCLUSIONS: TRPM4 protein expression is up-regulated in DLBCL cases compared to non-malignant B cells with preferential expression in ABC-DLBCL cases, and it confers significantly poorer DLBCL patient outcomes.

OriginalsprogEngelsk
TidsskriftHistopathology
Vol/bind71
Udgave nummer1
Sider (fra-til)98-111
Antal sider14
ISSN0309-0167
DOI
StatusUdgivet - jul. 2017

ID: 52353485